DEVELOPMENT AND OPTIMIZATION OF FAST DISSOLVING ORAL FILM CONTAINING ARIPIPRAZOLE
Abstract
The present investigation was aimed with the objective of developing fast dissolving oral films of Aripiprazole to attain quick onset of action for the better management of Schizophrenia. Fourteen formulations (F1-F14) of Aripiprazole mouth dissolving films by solvent-casting method using HPMC E5, HPMC E15, Maltodextrin, PG and PVA. Formulations were evaluated for their physical characteristics, thickness, folding endurance, tensile strength, disintegration time, drug content uniformity and drug release characteristics and found to be within the limits. Among the prepared formulations F13 showed minimum disintegration time 10 sec, maximum drug was released i.e. 99.49 ± 0.36% of drug within 8 min when compared to the other formulations and finalized as optimized formulation. FTIR data revealed that no interactions take place between the drug and polymers used in the optimized formulation. The in vitro dissolution profiles of marketed product and optimized formulation was compared and found to be the drug released was 20.73 ± 0.25 after 8 min. Therefore, it can be a good alternative to conventional Aripiprazole for immediate action. In vitro evaluation of the Aripiprazole fast dissolving oral films confirmed their potential as an innovative dosage form to improve delivery and quick onset of action of Aripiprazole. The mouth dissolving film is potentially useful for the treatment of Schizophrenia where the quick onset of action is desired.
Keywords:
Aripiprazole, Schizophrenia, Mouth dissolving films, disintegration time, HPMC.DOI
https://doi.org/10.25004/IJPSDR.2017.090607References
Chandak C. Master of Sci. Thesis Orally dissolving film of selegiline hydrochloride. London Island University.2009;5
Tripathi KD. Essential of medical pharmacology. 5th Edn, Jaypee Brothers medical Publisher. New Delhi, 2003, pp. 135-144.
Okabe H, Suzuki E, Sugiur Y, Yanagimoto K, Takanashi Y, Nogami E. Development of easily Swallowed film formulation. Int. J. pharma. 2008; 355: 62-66.
PeterChristoper GV. Formulation, Evaluation and in-vitro Release Studies of Aripiprazole Orally Disintegrating Tablets. Journal of Pharmacy Research. 2012; 5(4):2117-2121.
Gavaskar B, Vijayakumar S, Sharan G. Overview on fast dissolving oral films. Int. J. pharm. Pharma. Sci.2010; 2(3): 29-33.
Cilurzo F, Cupone IE, Minghetti P, Buratti S, Selmin F, Gennari CG, Montanari L. Nicotine Fast dissolving oral films Made of Maltodextrin. A feasibility studies. APPS Pharm Sci Tech. 2010; 11(4): 1511-1517.
Wale A, Weller PJ. Handbook of Pharmaceutical Excipients. 1994; 2: 24, 27, 352, 448.
Barnhart SD. Thin film oral dosage forms in Modified release. Drug Dev Tech. 2007; 1: 34-35.
Obermeier, T. Kohr, K. Kramer, K. Kolkkers. Oral quickly disintegrating film, which cannot be spit out for an antiemetic or antimigraine agent U.S. Patent 2008/0213343 A1, Sept 4.2008.
Nishimura M, Matsuura K, Tsukioka T, Yamashita H, Inagaki N, Sugiyama T, Itoh Y. In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm Sci. 2009; 368(2): 98–102.
Shimoda H, Taniguchi K. Preparation of fast dissolving oral thin film containing dexamethasone. A possible application to antiemesis during cancer chemotherapy.Europ J of Pharm and Biopharm. 2009; 73: 361-365.
Arya A, Chandra A. Fast Dissolving Oral Films: An Innovative Drug Delivery System and Dosage Form. Int J of Chem Tech Res. 2010; 2:576-583.
Published
Abstract Display: 815 
PDF Downloads: 639 How to Cite
Issue
Section
Copyright (c) 2017 S. Jyothi Sri, D.V.R.N Bhikshapathi
This work is licensed under a Creative Commons Attribution 4.0 International License.
